The Cool Down4h
Drugmaker reveals unsettling details of new strategy amid public outrage: 'It will be worse before it gets better'
Novo Nordisk revealed a stunning increase in pollution amid plans to boost production of its popular weight loss drug Wegovy.
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...
Stocktwits on MSN2d
Novo Nordisk Stock Slips After BofA, Morgan Stanley Slash Price Targets – But Retail Goes Contrarian
NYSE-listed shares of Novo Nordisk (NVO) traded over 1% lower on Friday afternoon after Bank of America lowered its price ...
Novo Nordisk to license obesity drug from Lexicon in up to $1 billion deal
Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...
Lexicon Pharmaceuticals Shares Soar on Novo Nordisk Licensing Deal
Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.
Novo Nordisk defends disappointing next-gen obesity drug: ‘It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...